BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12741725)

  • 1. Molecular mechanisms of fluoroquinolone resistance.
    Chen FJ; Lo HJ
    J Microbiol Immunol Infect; 2003 Mar; 36(1):1-9. PubMed ID: 12741725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis.
    Oyamada Y; Ito H; Inoue M; Yamagishi JI
    J Med Microbiol; 2006 Oct; 55(Pt 10):1395-1401. PubMed ID: 17005789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance-determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A.
    Hirose K; Hashimoto A; Tamura K; Kawamura Y; Ezaki T; Sagara H; Watanabe H
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3249-52. PubMed ID: 12234852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
    Beeton ML; Chalker VJ; Kotecha S; Spiller OB
    J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
    Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
    Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
    Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
    Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.
    Emrich NC; Heisig A; Stubbings W; Labischinski H; Heisig P
    J Antimicrob Chemother; 2010 Dec; 65(12):2530-3. PubMed ID: 20940181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types.
    Billal DS; Fedorko DP; Yan SS; Hotomi M; Fujihara K; Nelson N; Yamanaka N
    J Antimicrob Chemother; 2007 Jan; 59(1):28-34. PubMed ID: 17065188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of quinolone action and microbial response.
    Hawkey PM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():29-35. PubMed ID: 12702701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigating the fluoroquinolone molecular resistant mechanism of Stenotrophomonas maltophilia].
    Tao CM; Lü XJ; Li P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):266-9. PubMed ID: 16608091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-level resistance to fluoroquinolones linked to mutations in gyrA, parC, and parE in Salmonella enterica serovar Schwarzengrund isolates from humans in Taiwan.
    Baucheron S; Chaslus-Dancla E; Cloeckaert A; Chiu CH; Butaye P
    Antimicrob Agents Chemother; 2005 Feb; 49(2):862-3. PubMed ID: 15673791
    [No Abstract]   [Full Text] [Related]  

  • 20. Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
    Grohs P; Podglajen I; Gutmann L
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3024-7. PubMed ID: 15273116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.